2022
Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19
Kosinsky Y, Peskov K, Stanski DR, Wetmore D, Vinetz J. Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19. Microbiology Spectrum 2022, 10: e02167-21. PMID: 35412356, PMCID: PMC9047529, DOI: 10.1128/spectrum.02167-21.Peer-Reviewed Original ResearchConceptsFOY-251SARS-CoV-2 cell entryCamostat mesylateInhibition of TMPRSS2Viral loadClinical trialsCOVID-19Viral entrySerine protease inhibitorSpike proteinCell entryMultiple clinical trialsPharmacokinetic-pharmacodynamic modelSARS-CoV-2 viral entryPK/PDSARS-CoV-2Protease inhibitorsOne-compartmentCell surface serine proteaseViral entry inhibitionTMPRSS2 inhibitionViral surface spike proteinsAcute exacerbationSemi-mechanistic pharmacokinetic-pharmacodynamic modelsSARS-CoV-2 coronavirus
2016
Epidemiology of Plasmodium vivax Malaria in Peru
Rosas-Aguirre A, Gamboa D, Manrique P, Conn JE, Moreno M, Lescano AG, Sanchez JF, Rodriguez H, Silva H, Llanos-Cuentas A, Vinetz JM. Epidemiology of Plasmodium vivax Malaria in Peru. American Journal Of Tropical Medicine And Hygiene 2016, 95: 133-144. PMID: 27799639, PMCID: PMC5201219, DOI: 10.4269/ajtmh.16-0268.Peer-Reviewed Original ResearchConceptsMalaria transmissionP. vivaxMalaria controlPlasmodium falciparum malaria casesMicroscopy-confirmed casesP. vivax malaria transmissionFalciparum malaria casesPlasmodium vivax malariaVivax malaria transmissionPublic health problemGlucose-6-phosphate dehydrogenase deficiencyFuture malaria controlImplementation of surveillanceCombination therapyVivax malariaClinical trialsMalaria casesPlasmodium vivaxElimination effortsHealth problemsP. falciparumMosquito transmissionDehydrogenase deficiencyVivaxOngoing surveillance activities